Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
[HTML][HTML] NAFLD and cardiovascular diseases: a clinical review
P Kasper, A Martin, S Lang, F Kuetting… - Clinical research in …, 2021 - Springer
Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study
Background & Aims An international expert panel proposed a new definition for metabolic
dysfunction–associated fatty liver disease (MAFLD) as a name change from nonalcoholic …
dysfunction–associated fatty liver disease (MAFLD) as a name change from nonalcoholic …
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This
narrative Review provides an overview of the current literature to support the notion that …
narrative Review provides an overview of the current literature to support the notion that …
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of
the world's adult population. Several cohort studies have consistently documented that …
the world's adult population. Several cohort studies have consistently documented that …
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …
problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is …
[HTML][HTML] An international multidisciplinary consensus statement on MAFLD and the risk of CVD
XD Zhou, G Targher, CD Byrne, V Somers… - Hepatology …, 2023 - Springer
Background Fatty liver disease in the absence of excessive alcohol consumption is an
increasingly common condition with a global prevalence of~ 25–30% and is also associated …
increasingly common condition with a global prevalence of~ 25–30% and is also associated …
[HTML][HTML] Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases
J Gutiérrez-Cuevas, A Santos… - International Journal of …, 2021 - mdpi.com
Obesity is now a worldwide epidemic ensuing an increase in comorbidities' prevalence,
such as insulin resistance, type 2 diabetes (T2D), metabolic dysfunction-associated fatty …
such as insulin resistance, type 2 diabetes (T2D), metabolic dysfunction-associated fatty …
[HTML][HTML] Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents
with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes …
with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes …